chronic inflammatory disorders

By Targets:	Akt (2) Apoptosis (2) Bacterial (2) c-Fms (1) Caspase (2) Endogenous Metabolite (2) Fungal (2) HDAC (1) Heme Oxygenase (HO) (2) HSP (2) Interleukin Related (4) Keap1-Nrf2 (3) Lipoxygenase (1) LPL Receptor (2) MMP (3) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (2) PARP (2) Phosphodiesterase (PDE) (1) Proteasome (2) Reactive Oxygen Species (ROS) (2) Reference Standards (2) SOD (2) TGF-beta/Smad (2) TGF-β Receptor (2) TNF Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (5) Infection (2) Inflammation/Immunology (16) Metabolic Disease (5) Neurological Disease (6)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108841

Raleukin 50+ Cited Publications Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-N0576

Solanesol 2 Publications Verification	Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP	Neurological Disease Metabolic Disease Inflammation/Immunology
Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .

HY-N6013

Aloin (mixture of A&B)	MMP Proteasome Keap1-Nrf2 TGF-beta/Smad Interleukin Related SOD Bacterial Fungal	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma .

HY-N0444

Rubiadin	Reactive Oxygen Species (ROS)	Inflammation/Immunology
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-19772

GSK3117391 ESM-HDAC391; CHR-5154; HDAC-IN-3	HDAC c-Fms	Inflammation/Immunology
GSK3117391 (ESM-HDAC391; CHR-5154; HDAC-IN-3) is an orally active HDAC inhibitor with a IC₅₀ of 55 nM. Using esterase-sensitive motif technology, GSK3117391 is selectively converted into its active acid metabolite HDAC189 in cells expressing carboxylesterase-1. GSK3117391 induces sustained global protein acetylation in monocytes, inhibits the production of proinflammatory cytokines, depletes circulating monocytes, downregulates the expression of CSF1R, and inhibits monocyte adhesion and differentiation. GSK3117391 can be used in the research of chronic inflammatory diseases .

HY-P3970A

KRFK TFA 4 Publications Verification	TGF-β Receptor	Inflammation/Immunology
KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach .

HY-P3970

KRFK	TGF-β Receptor	Inflammation/Immunology
KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach .

HY-139555

Zectivimod	LPL Receptor	Inflammation/Immunology
Zectivimod is a sphingosine-1-phosphate receptor agonist. Zectivimod can be used for the research of autoimmune diseases，chronic inflammatory diseases and immunoregulation disorders .

HY-N0576R

Solanesol (Standard)	Reference Standards Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP	Neurological Disease Metabolic Disease Inflammation/Immunology
Solanesol (Standard) is the analytical standard of Solanesol (HY-N0576). This product is intended for research and analytical applications. Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .

HY-150579

Keap1-Nrf2-IN-13	Keap1-Nrf2	Inflammation/Immunology Cancer
Keap1-Nrf2-IN-13 is a Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with an IC₅₀ value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forming hydrogen bond with the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers .

HY-175275

10-Butyl Ether Minocycline BEM	MMP Lipoxygenase Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
10-Butyl Ether Minocycline (BEM), a Minocycline (HY-17412A) derivative, is an MMP-8 and MMP-9 inhibitor with IC₅₀s of 69.4 µM and 47.0 µM, respectively. 10-Butyl Ether Minocycline suppresses LPS (HY-D1056)-induced microglial activation. 10-Butyl Ether Minocycline inhibits VEGF-induced endothelial cell migration and L-Glutamine (HY-N0390)-induced ROS levels. 10-Butyl Ether Minocycline significantly reduces alcohol consumption in the Chronic Intermittent Ethanol (CIE) mouse model of alcohol dependence. 10-Butyl Ether Minocycline can be used for the study of neuroimmune-inflammatory diseases and Alcohol use disorder (AUD) .

HY-N6013R

Aloin (mixture of A&B) (Standard)	Reference Standards Proteasome MMP Keap1-Nrf2 TGF-beta/Smad Interleukin Related SOD Fungal Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Aloin (mixture of A&B) (Standard) is the analytical standard of Aloin (mixture of A&B) (HY-N6013). This product is intended for research and analytical applications. Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma .

HY-N9275

Isopicropodophyllin	Others	Metabolic Disease Inflammation/Immunology
Isopicropodophyllin is a natural compound that can be used for metabolic or chronic inflammatory disorder research .

HY-N16735

Isofouquierol	NO Synthase	Inflammation/Immunology
Isofouquierol is a selective inhibitor targeting nitric oxide (NO) production with anti-inflammatory activity. Isofouquierol blocks NO overproduction by inhibiting the inducible nitric oxide synthase (iNOS)-related pathway. Isofouquierol can be used in the study of inflammation-related diseases (such as chronic inflammation, immune disorders) .

HY-18334

GSK-2262167 sodium	LPL Receptor	Neurological Disease Inflammation/Immunology
GSK-2262167 sodium is a selective S1P1 receptor agonist. GSK-2262167 sodium is used for research on inflammatory and immune diseases .

HY-179503

PDE/TRPA1/CHIT1-IN-1	Phosphodiesterase (PDE) TRP Channel NOD-like Receptor (NLR) NF-κB TNF Receptor Interleukin Related	Inflammation/Immunology
PDE/TRPA1/CHIT1-IN-1 is a phosphodiesterases (PDEs), TRPA1, and hCHIT1 (K_D of 37.7 μM) inhibitor. PDE/TRPA1/CHIT1-IN-1 is a broad-spectrum PDE inhibitor, potently targeting key isoforms including PDE4B, PDE7A, PDE3A, and PDE8A with IC₅₀s of 15.54, 15.15, 8.39 and 16.46 μM. PDE/TRPA1/CHIT1-IN-1 suppresses NLRP3 inflammasome activation and inhibits NF-κB phosphorylation, downregulating the expression of pro-inflammatory genes (TNF-α and IL-6) in vivo. PDE/TRPA1/CHIT1-IN-1 can be used for chronic obstructive pulmonary disease (COPD) and related inflammatory lung disorders research .

Cat. No.	Product Name

HY-L237

Pattern Recognition Receptors Library	313 compounds
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions. MCE has cataloged 313 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.

Pattern Recognition Receptors Library

313 compounds

Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.

MCE has cataloged 313 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.

HY-L046

Anti-Cardiovascular Disease Compound Library	2,282 compounds
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 2,282 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Anti-Cardiovascular Disease Compound Library

2,282 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 2,282 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Cat. No.	Product Name	Target	Research Area